Missey, Florian
Ejneby, Malin Silverå
Ngom, Ibrahima
Donahue, Mary J.
Trajlinek, Jan
Acerbo, Emma
Botzanowski, Boris
Cassarà, Antonino M.
Neufeld, Esra
Glowacki, Eric D.
Shangold, Lee
Hanes, William M.
Williamson, Adam
Funding for this research was provided by:
HORIZON EUROPE European Research Council (grant agreement No 716867)
European Research Council (834677 “e-NeuroPharma” ERC-2018-ADG)
Article History
Received: 29 May 2023
Accepted: 26 July 2023
First Online: 9 August 2023
Declarations
:
: Mice experiments were approved by the European Council Directive EU2010/63 and French Ethics committee (comité d’éthique en experimentation animale n°70 - Williamson, n. APAFIS 20359–2019041816357133). Regarding human clinical trial, it was realized with the agreement of the International Conference on Harmonisation Good Clinical Practice (ICH GCP), applicable United States Code of Federal Regulations (CFR) and followed the approved BRANY IRB File # 22-02-636-1279. All participants were given an informed consent before the trial explained all procedures and expected outcome of treatment or potential adverse effects (no adverse effects were seen during this trial).
: Not applicable.
: E.N is shareholder and board member of TI Solutions AG, a company established to support TI researchers with suitable hardware and software technologies. A.W., W.M.H. and L.S. are the shareholders of Somnial Inc, the owner of the patents protecting the technology described in this manuscript. The authors declare no other competing financial interests.